References
- Tiwari R, Dhama K, Sharun K, et al. COVID-19: animals, veterinary and zoonotic links. Vet Q. 2020;40(1):169–182. DOI:https://doi.org/10.1080/01652176.2020.1766725.
- Segreto R, Deigin Y. The genetic structure of SARS-CoV-2 does not rule out a laboratory origin: SARS-COV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation. Bioessays. 2021;43(3):e2000240.
- Holmes EC, Goldstein SA, and Rasmussen AL, et al. The origins of SARS-CoV-2: a critical review. Cell. 2021;184:2848–4856. DOI:https://doi.org/10.1016/j.cell.2021.08.017. 1097-4172
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;4(20):271–280e278. DOI:https://doi.org/10.1016/j.cell.2020.02.052.
- Baek WK, Sohn SY, Mahgoub A, et al. A comprehensive review of severe acute respiratory syndrome Coronavirus 2. Cureus. 2020;12(5):e7943.
- Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395(10229):1014–1015. DOI:https://doi.org/10.1016/S0140-6736(20)30633-4. London, England
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI:https://doi.org/10.1016/S0140-6736(20)30566-3. London, England
- Gao Y, Chen Y, Liu M, et al. Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):e93–e95.
- Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Respir Med. 2020;8(6):547–548.
- Abedi V, Olulana O, Avula V, et al., Racial, economic, and health inequality and COVID-19 infection in the United States. J Racial Ethn Health Disparities. 8(3): 732–742. 2021. DOI:https://doi.org/10.1007/s40615-020-00833-4. .
- Wiersinga WJ, Rhodes A, and Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793.
- Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511. DOI:https://doi.org/10.1126/science.abc8511. New York, N.Y.
- Yan X, Chen G, Jin Z, et al. Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19. J Med Virol. 2022;94(1):380–383. DOI:https://doi.org/10.1002/jmv.27274.
- Legros V, Denolly S, and Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18:318–327. DOI:https://doi.org/10.1038/s41423-020-00588-2.
- Sandberg JK, Varnaitė R, Christ W, et al. SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. Clin Transl Immunology. 2021;10(7):e1306. DOI:https://doi.org/10.1002/cti2.1306.
- Dobano C, Ramirez-Morros A, Alonso S, et al. Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. BMC Med. 2021;19(1):155. DOI:https://doi.org/10.1186/s12916-021-02032-2.
- Gaebler C, Wang Z, and Lorenzi J, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:eabf1555. DOI:https://doi.org/10.1038/s41586-021-03207-w.
- Hartley G, Edwards ESJ, and Aui P, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5. DOI:https://doi.org/10.1126/sciimmunol.abf8891.
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. DOI:https://doi.org/10.1126/science.abf4063. New York, N.Y.
- Fröberg J, Gillard J, and Philipsen R, et al. SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms. Nat Commun. 2021;12:5621. DOI:https://doi.org/10.1038/s41467-021-25949-x.
- Kowitdamrong E, Puthanakit T, Jantarabenjakul W, et al. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PloS one. 2020;15(10):e0240502. DOI:https://doi.org/10.1371/journal.pone.0240502.
- Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848. DOI:https://doi.org/10.1038/s41591-020-0897-1.
- Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–1087. DOI:https://doi.org/10.1056/NEJMc2025179.
- Marot S, Malet I, and Leducq V, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021;12:844. DOI:https://doi.org/10.1038/s41467-021-21111-9.
- Flieder T, Vollmer T, Muller B, et al. Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. PloS one. 2021;16(2):e0247665. DOI:https://doi.org/10.1371/journal.pone.0247665.
- Yang Y, Wang X, Du RH, et al. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses. Emerg Microbes Infect. 2021;10(1):905–912. DOI:https://doi.org/10.1080/22221751.2021.1919032.
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al., Robust T Cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 183(1): 158–168 e114. 2020. DOI:https://doi.org/10.1016/j.cell.2020.08.017. .
- Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-Specific immune memory persists after mild COVID-19. Cell. 2020;184(1):169–183e117. DOI:https://doi.org/10.1016/j.cell.2020.11.029.
- Bloise S, Marcellino A, Testa A, et al. Serum IgG levels in children 6 months after SARS-CoV-2 infection and comparison with adults. Eur J Pediatr. 2021;180(11):3335–3342. DOI:https://doi.org/10.1007/s00431-021-04124-w.
- Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med. 2020;12(564):eabd5487. DOI:https://doi.org/10.1126/scitranslmed.abd5487.
- Liu W, R R, B-r F, et al. Predictors of nonseroconversion after SARS-CoV-2 Infection. Emerg Infect Dis. 2021;27(9):2454–2458. DOI:https://doi.org/10.3201/eid2709.211042.
- Pedroso C, Vaz S, Netto EM, et al. Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response. Braz J Infect Dis. 2021;25(4):101603. DOI:https://doi.org/10.1016/j.bjid.2021.101603.
- Hill A, Garratt A, and Levi J, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infect Dis. 2021;8:ofab358. DOI:https://doi.org/10.1093/ofid/ofab358.
- Ali AM, Ali KM, and Fatah MH, et al. SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. New Microbes New Infect. 2021;43:100926.
- Marklund E, Leach S, Axelsson H, et al. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PloS one. 2020;15(10):e0241104. DOI:https://doi.org/10.1371/journal.pone.0241104.
- Cota G, Freire ML, de Souza CS, et al. Diagnostic performance of commercially available COVID-19 serology tests in Brazil. Int J Infect Dis. 2020;101:382–390.
- Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–1734. DOI:https://doi.org/10.1056/NEJMoa2026116.
- Lumley SF, Wei J, O’Donnell D, et al. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin Infect Dis. 2021;73(3):e699–e709. DOI:https://doi.org/10.1093/cid/ciab004.
- Guo X, Zeng L, Huang Z, et al. Longer duration of SARS-CoV-2 infection in a case of mild COVID-19 with weak production of the specific IgM and IgG antibodies. Front Immunol. 2020;11:1936.
- Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–1607. DOI:https://doi.org/10.1038/s41564-020-00813-8.
- Roltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):eabe0240. DOI:https://doi.org/10.1126/sciimmunol.abe0240.
- McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020;5(18):e142386. DOI:https://doi.org/10.1172/jci.insight.142386.
- Naaber P, Hunt K, Pesukova J, et al. Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: comparison of nine tests in relation to clinical data. PloS one. 2020;15(10):e0237548. DOI:https://doi.org/10.1371/journal.pone.0237548.
- Chua KYL, Vogrin S, Bittar I, et al. Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection. Pathology. 2020;52(7):778–782. DOI:https://doi.org/10.1016/j.pathol.2020.09.003.
- Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270–274. DOI:https://doi.org/10.1038/s41586-020-2598-9.
- Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073–1078. DOI:https://doi.org/10.1038/s41587-020-0631-z.
- Perera RAPM, Ko R, Tsang OTY, et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera. J Clin Microbiol. 2021 Jan 21;59(2):e02504–20. doi:https://doi.org/10.1128/JCM.02504-20.
- Septisetyani EP, Prasetyaningrum PW, Anam K, et al. SARS-CoV-2 antibody neutralization assay platforms based on epitopes sources: live virus, pseudovirus, and recombinant s glycoprotein RBD. Immune Netw. 2021 Dec;21(6):e39. doi:https://doi.org/10.4110/in.2021.21.e39-.
- Bylicki O, Delarbre D, and Mayet A, et al. Neutralizing antibodies response to SARS-CoV-2 are persistent 9 months post symptom onset in mild or asymptomatic patients. Int J Infect Dis. 2021;112:8–12. DOI:https://doi.org/10.1016/j.ijid.2021.09.002.
- Dehgani-Mobaraki P, Kamber Zaidi A, Porreca A, et al. Neutralizing antibody responses against SARS-CoV-2 spike receptor-binding domain 13 months after the recovery from the disease, Ann Ig. 2021 Aug 3. doi:https://doi.org/10.7416/ai.2021.2466. Epub ahead of print. PMID: 34328495.
- Gattinger P, Niespodziana K, Stiasny K, et al. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes. Allergy. 2022;77. 1398-9995 DOIhttps://doi.org/10.1111/all.15066.
- Kawasuji H, Morinaga Y, Tani H, et al. Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19. Sci Rep. 2021;11(1):16535.
- Faggiano F, Rossi M, and Cena T, et al. An outbreak of COVID-19 among mRNA-Vaccinated nursing home residents. Vaccines (Basel). 2021;9:859. DOI:https://doi.org/10.3390/vaccines9080859.
- Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–1484. DOI:https://doi.org/10.1056/NEJMoa2109072.
- Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022. DOI:https://doi.org/10.1016/j.cell.2022.01.015.
- Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193. Epub 42022 Feb 41591. DOI:https://doi.org/10.1038/s41590-41021-01122-w
- Zhou Y, Liu Z, Li S, et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021;34(5):108699. DOI:https://doi.org/10.1016/j.celrep.2021.108699.
- Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?. Swiss Med Wkly. 2020;150:w20249. DOI:https://doi.org/10.4414/smw.2020.20249. eCollection 22020 Apr.
- Lambert PH, Ambrosino DM, Andersen SR, et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 2020;38(31):4783–4791. DOI:https://doi.org/10.1016/j.vaccine.2020.05.064.
- Junqueira C, Crespo Ã, Ranjbar S, et al. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. Res Sq. 2021; Preprint (2921). DOI:https://doi.org/10.21203/rs.3.rs-153628/v1.
- Rothan HA, Byrareddy SN. The potential threat of multisystem inflammatory syndrome in children during the COVID-19 pandemic. Pediatr Allergy Immunol. 2021;32(1):17–22.
- Guida M, Terracciano D, Cennamo M, et al. COVID-19 vaccine mRNABNT162b2 elicits human antibody response in milk of breastfeeding women. Vaccines (Basel). 2021;9:785. DOI:https://doi.org/10.3390/vaccines9070785.
- Duncombe CJ, McCulloch DJ, and Shuey KD, et al. Dynamics of breast milk antibody titer in the six months following SARS-CoV-2 infection. J Clin Virol. 2021;142:104916. DOI:https://doi.org/10.1016/j.jcv.2021.104916.
- Juncker HG, Romijn M, Loth VN, et al. Human milk antibodies against SARS-CoV-2: a longitudinal follow-up study. J Hum Lact. 2021;37(3):485–491. DOI:https://doi.org/10.1177/08903344211030171.
- Douxfils J, Gillot C, and De Gottal É, et al. Efficient maternal to neonate transfer of neutralizing antibodies after SARS-CoV-2 vaccination with BNT162b2: a case-report and discussion of the literature. Vaccines (Basel). 2021;9:907. DOI:https://doi.org/10.3390/vaccines9080907.
- Editorial. Facing up to long COVID. Lancet. 2020;396(10266):1861. DOI:https://doi.org/10.1016/S0140-6736(20)32662-3. Editorial
- Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–264.
- Jennings G, Monaghan A, Xue F, et al. A systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs. Post-COVID-19 syndrome. J Clin Med. 2021;10(24):5913.
- Charfeddine S, Ibn Hadj Amor H, and Jdidi J, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:745758. DOI:https://doi.org/10.3389/fcvm.2021.745758.
- Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. DOI:https://doi.org/10.1186/s12933-021-01359-7.
- García-Abellán J, Padilla S, and Fernández-González M, et al. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol. 2021;41:1490–1501. DOI:https://doi.org/10.1007/s10875-021-01083-7.
- Augustin M, Schommers P, and Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. DOI:https://doi.org/10.1016/j.lanepe.2021.100122.
- Ameratunga R, Woon ST, Jordan A, et al. Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection. Expert Rev Clin Immunol. 2021;17(5):421–430. DOI:https://doi.org/10.1080/1744666X.2021.1905525.
- Ameratunga R, Longhurst H, Steele R, et al. Common variable immunodeficiency disorders, T-Cell responses to SARS-CoV-2 vaccines, and the risk of chronic COVID-19. J Allergy Clin Immunol Pract. 2021;9(10):3575–3583. DOI:https://doi.org/10.1016/j.jaip.2021.06.019.
- Hensley MK, Bain WG, Jacobs J, et al., Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-Cell therapy recipient: a case study. Clin Infect Dis. 73(3): e815–e821. 2021. DOI:https://doi.org/10.1093/cid/ciab072. .
- Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383(23):2291–2293. DOI:https://doi.org/10.1056/NEJMc2031364.
- Chen L, Zody MC, Di Germanio C, et al. Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. mSphere. 2021;6(4):e0048021. DOI:https://doi.org/10.1128/mSphere.00480-21.
- Ferri C, Ursini F, and Gragnani L, et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. J Autoimmun. 2021;125:102744. DOI:https://doi.org/10.1016/j.jaut.2021.102744.
- Brosh-Nissimov T, Orenbuch-Harroch E, and Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27:1652–1657. DOI:https://doi.org/10.1016/j.cmi.2021.06.036.
- Ameratunga R, Ahn Y, Steele R, et al. The natural history of untreated primary hypogammaglobulinemia in adults: implications for the diagnosis and treatment of Common Variable Immunodeficiency Disorders (CVID). Front Immunol. 2019;10:1541.
- Ameratunga R, Allan C, Woon ST. Defining common variable immunodeficiency disorders in 2020. Immunol Allergy Clin North Am. 2020;40(3):403–420.
- Ameratunga R, Jordan A, Cavadino A, et al. Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study. Clin Exp Immunol. 2021;204(3):352–360. DOI:https://doi.org/10.1111/cei.13595.
- Amodio D, Ruggiero A, Sgrulletti M, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850.
- Salinas AF, Mortari EP, Terreri S, et al. SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. J Clin Immunol. 2021;41(8):1709–1722. DOI:https://doi.org/10.1007/s10875-021-01133-0.
- Esenboga S, Ocak M, Akarsu A, et al. COVID-19 in patients with primary immunodeficiency. J Clin Immunol. 2021;41(7):1515–1522. DOI:https://doi.org/10.1007/s10875-021-01065-9.
- Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585. doi: https://doi.org/10.1126/science.abd4585.
- Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020Oct 23;370(6515):eabd4570. doi: https://doi.org/10.1126/science.abd4570
- Quinti I, Lougaris V, Milito C, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146(1):211–213 e214. DOI:https://doi.org/10.1016/j.jaci.2020.04.013.
- Jin H, Reed JC, Liu STH, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(10):3594–3596 e3593. DOI:https://doi.org/10.1016/j.jaip.2020.08.059.
- Mira E, Yarce OA, Ortega C, et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(8):2793–2795. DOI:https://doi.org/10.1016/j.jaip.2020.06.046.
- Van Damme KFA, Tavernier S, and Van Roy N, et al. Case report: convalescent plasma, a targeted therapy for patients with CVID and Severe COVID-19. Front Immunol. 2020;11:596761. DOI:https://doi.org/10.3389/fimmu.2020.596761.
- Jones JM, Stone M, and Sulaeman H, et al. Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations. JAMA. 1538-3598 2020-July 2021;326:1400–1409. DOI:https://doi.org/10.1001/jama.2021.15161.
- Abraham J. Passive antibody therapy in COVID-19. Nat Rev Immunol. 2020;20(7):401–403.
- Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021;29(4):529–539.e523. DOI:https://doi.org/10.1016/j.chom.2021.03.002.
- Mlcochova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114–119.
- Tea F, Ospina Stella A, Aggarwal A, et al. SARS-CoV-2 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants. PLoS Med. 2021;18(7):e1003656. DOI:https://doi.org/10.1371/journal.pmed.1003656.
- Choi A, Koch M, Wu K, et al. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. J Virol. 2021;95(23):e0131321. DOI:https://doi.org/10.1128/JVI.01313-21.
- Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021 Nov;27(11):2012-2024. doi: https://doi.org/10.1038/s41591-021-01488-2
- Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;5(5):CD013600. DOI:https://doi.org/10.1002/14651858.CD013600.
- Focosi D, Franchini M, and Pirofski LA, et al. COVID-19 convalescent plasma is more than neutralizing antibodies: a narrative review of potential beneficial and detrimental co-factors. Viruses. 2021;13:1594.
- Bates TA, Leier HC, Lyski ZL, et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nat Commun. 2021;12(1):5135. DOI:https://doi.org/10.1038/s41467-021-25479-6.
- Aria H, Mahmoodi F, and Ghaheh HS, et al. Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: a systematic review. Anal Biochem. 2022;4. 1096-0309.
- Corti D, Purcell LA, Snell G, et al. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184:3086–3108.
- Ullah I, Prévost J, Ladinsky MS, et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. 2021;54:2143–2158.e15. DOI:https://doi.org/10.1016/j.immuni.2021.08.015.
- Liu Z, VanBlargan LA, Bloyet LM, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;27(21):447–488.e444.
- Yuan M, Huang D, Lee CD, et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021;373(6556):818–823. DOI:https://doi.org/10.1126/science.abh1139. New York, N.Y.
- Chen RE, Winkler ES, Case JB, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021;596(7870):103–108. DOI:https://doi.org/10.1038/s41586-021-03720-y.
- Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, et al. Emergence of E484K mutation following bamlanivimab monotherapy among high-risk patients infected with the alpha variant of SARS-CoV-2. Viruses. 2021;13(8):1462. DOI:https://doi.org/10.3390/v13081642.
- Kreuzberger N, Hirsch C, and Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021;9:CD013825. DOI:https://doi.org/10.1002/14651858.CD013825.pub2. 1469-493X.
- Xiang Y, Nambulli S, Xiao Z, et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020;370(6523):1479–1484. DOI:https://doi.org/10.1126/science.abe4747. New York, N.Y.
- Planas D, Saunders NA, and Maes PA, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;10. 1038/s41586-021-04389-z.
- Liu L, Iketani S, and Guo YA-OX, et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Naturev 2021;10:. . https://doi.org/10.1038/s41586-021-04388-0
- Goel R, Apostolidis SA, and Painter M, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6. DOI:https://doi.org/10.1126/sciimmunol.abi6950.
- Pegu A, O’Connell S, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372–1377. New York, N.Y. 2921. DOI:https://doi.org/10.1126/science.abj4176.
- Bar-On YM, Goldberg Y, and Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385. 1533-4406.
- Benning L, Töllner M, and Hidmark A, et al. Heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers. Vaccines (Basel). 2021;9:857. DOI:https://doi.org/10.3390/vaccines9080857.
- Dangi T, Class J, Palacio N, et al. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep. 2021;36(10):109664.
- Erice A, Varillas-Delgado D, and Caballero C. Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults. Clin Microbiol Infect. 2022;28:139.e131–139.e134. DOI:https://doi.org/10.1016/j.cmi.2021.08.023.
- Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance - eight U.S. locations. 2020. December -August 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169. doi: https://doi.org/10.15585/mmwr.mm7034e4.
- Harder T, Külper-Schiek W, and Reda S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis. Euro Surveill. 2021;1 January to 1 January ;26:2100920.
- Spicer KB, Glick C, and Cavanaugh AM, et al. Protective immunity after natural infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) - Kentucky, USA, 2020. Int J Infect Dis. 2022;114(114):21–28. DOI:https://doi.org/10.1016/j.ijid.2021.10.010.
- Feder K, Patel A, and Vepachedu VR, et al. Association of E484K spike protein mutation with SARS-CoV-2 infection in vaccinated persons. Clin Infect Dis. 2021 Sep 2;ciab762. doi: https://doi.org/10.1093/cid/ciab762
- Chen LL, Lu L, and Choi CY, et al. Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination. Clin Infect Dis. 2021;26:656. DOI:https://doi.org/10.1093/cid/ciab656.
- Ameratunga R, Lehnert K, Leung E, et al. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. N Z Med J. 2020;133(1515):112–118.
- Ameratunga R, Woon ST, Steele R, et al. Perspective: the nose and the stomach play a critical role in the NZACE2-Patari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. Expert Rev Clin Immunol. 2021;17(6):553–560. DOI:https://doi.org/10.1080/1744666X.2021.1912596.
- Goncalves D, Mezidi M, Bastard P, et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunology. 2021;10(8):e1327. DOI:https://doi.org/10.1002/cti2.1327.
- Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020;115(10):1707–1715.
- Melvin W, Audu C, Davis F, et al. Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):e2101071118. doi: https://doi.org/10.1073/pnas.2101071118.
- Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48):eabd2071. DOI:https://doi.org/10.1126/sciimmunol.abd2071.
- Meckiff BJ, Ramirez-Suastegui C, Fajardo V, et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell. 2020;183(5):1340–1353 e1316. DOI:https://doi.org/10.1016/j.cell.2020.10.001.
- Bacher P, Rosati E, Esser D, et al. Low-Avidity CD4(+) T Cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity. 2020;53(6):1258–1271 e1255. DOI:https://doi.org/10.1016/j.immuni.2020.11.016.
- Golovkin A, Kalinina O, and Bezrukikh V, et al. Imbalanced immune response of T-Cell and B-Cell subsets in patients with moderate and severe COVID-19. Viruses. 2021;13:1966. DOI:https://doi.org/10.3390/v13101966.
- Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in Acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012 e1019. DOI:https://doi.org/10.1016/j.cell.2020.09.038.
- Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728. DOI:https://doi.org/10.1016/j.celrep.2021.108728.
- Bertoletti A, Le Bert N, Qui M, et al. SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol Immunol. 2021;18(10):2307–2312.
- Swadling L, Diniz MO, and Schmidt N, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2022;601:110–117. DOI:https://doi.org/10.1038/s41586-021-04186-8.
- Zuo J, Dowell AC, Pearce H, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nature. 2021;22(5):620–626.
- Cassaniti I, Percivalle E, Bergami F, et al. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. Clin Microbiol Infect. 2021;27(7):1029–1034. DOI:https://doi.org/10.1016/j.cmi.2021.03.010.
- Chen J, Liu X, and Zhang X, et al. Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. Clin Transl Immunology. 2021;10:e1319. DOI:https://doi.org/10.1002/cti2.1319.
- Bonifacius A, Tischer-Zimmermann S, Dragon AC, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54(2):340–354 e346. DOI:https://doi.org/10.1016/j.immuni.2021.01.008.
- Björkander S, Du L, and Zuo F, et al. SARS-CoV-2 specific B- and T-cell immunity in a population-based study of young Swedish adults. J Allergy Clin Immunol. 2021;21:S0091–6749.
- Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43–55. DOI:https://doi.org/10.1016/S1473-3099(21)00460-6.
- Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022 Feb 3;185(3):447-456.e11. doi: https://doi.org/10.1016/j.cell.2021.12.032